Pfizer Limited (PFIZER) · mywealthgrid

Loading page…

About

Pfizer Limited is a pharmaceutical company operating in the Healthcare sector, with a market capitalisation of ₹22,278 Cr. The company generates quarterly revenues of approximately ₹600–650 Cr and has sustained operating margins above 35% with no outstanding debt.

Face value: ₹10

Market cap

₹17,635 Cr

P/E

24.0×

P/B

4.2×

Dividend yield

1.9%

ROE

17.2%

ROCE

24%

Debt / equity

OPM

35.9%

EPS (TTM)

₹160.7

Book value

₹918.7

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

PE ratio of 30.3 is elevated for pharma; verify whether valuation is justified by earnings growth or reflects market concerns about future sustainability.
Stock returned -2.89% over one year despite revenue growth of 16% and margin expansion to 37.9%; determine whether this reflects valuation compression or undisclosed headwinds.
Quarterly net profit ranges from ₹127.6 Cr (Dec 2024) to ₹204.5 Cr (Jun 2026); verify whether this volatility is seasonal or signals inconsistent execution.
Promoter holding of 63.92% concentrates ownership; verify disclosure standards for related-party transactions and board independence.

Generated analysis · source review pending

Growth drivers

Revenue expanded 16% from ₹562.9 Cr (Jun 2024) to ₹653.2 Cr (Jun 2026), demonstrating volume or price gains over two years.
Operating margin improved 637 basis points from 31.53% (Jun 2024) to 37.9% (Jun 2026), reflecting better cost management or product mix.
EPS grew 35.6% from ₹32.94 (Jun 2024) to ₹44.69 (Jun 2026), outpacing revenue growth via margin expansion.
Consistent dividend declarations (2023–2026) indicate reliable cash generation; verify payout policy and sustainability.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹3,858.9-1.4%1Y

Quick read

rule-based

Pros

+High return on capital employed of 22.2%
+Healthy operating margin of 35.9%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 109.1×
+Dividend payout of 46.6% of profit
+High promoter holding of 63.9% with no pledge

Cons

−Modest revenue growth of 2.4% a year over the last 5 years

Research score

Structured signal from quality, growth, valuation and momentum.

55/100

Business quality: 82
Growth: 25

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2,017	2,022	1,980	2,082	2,152	2,239	2,611	2,425	2,193	2,281	2,520
COGS	-785	-796	740	380	792	798	948	874	793	810	884
Gross profit	—	—	1,241	1,701	1,359	1,441	1,663	1,551	1,401	1,471	1,635
	2,371	2,486	740	1,136	787	729	827	742	765	731	731
	431	333	500	565	573	712	836	809	635	740	904
OPM %	21.4%	16.5%	25.3%	27.2%	26.6%	31.8%	32%	33.4%	29%	32.5%	35.9%
Depreciation	124	—	66	71	103	109	115	106	62	61	58
Interest	1	1	0	1	11	15	10	13	15	8	9
	86	101	114	167	184	81	63	134	188	345	139
Profit before tax	402	517	548	660	642	669	773	824	746	1,016	976
Tax	179	180	188	231	133	171	160	200	195	248	253
Tax %	44.6%	34.8%	34.3%	35%	20.8%	25.6%	20.7%	24.3%	26.1%	24.5%	26%
	223	337	360	429	509	498	613	624	551	768	722
PAT margin %	11.1%	16.7%	18.2%	20.6%	23.7%	22.2%	23.5%	25.7%	25.1%	33.7%	28.7%
EPS (₹)	48.7	73.6	78.7	93.8	111.3	108.8	133.9	136.4	120.5	167.8	157.9
EPS adjusted (₹)	48.7	73.6	78.7	93.8	111.3	108.8	133.9	136.4	120.5	167.8	157.9
	30.8%	27.2%	25.4%	24%	296.5%	32.2%	48.5%	29.3%	29%	98.3%	47.5%
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	46	46	46	46	46	46	46	46	46	46	46
Reserves	1,876	2,373	2,637	2,966	3,350	2,347	2,819	3,162	3,550	4,172	4,157
	3	3	3	3	3	3	3	3	3	3	3
	619	840	1,004	926	1,007	870	1,034	791	631	691	716
Total equity & liabilities	2,543	3,261	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911	4,922
	944	867	917	854	942	865	841	749	713	724	678
CWIP	13	4	—	—	1	3	1	8	0	8	20
Investments	0	0	0	0	0	30	28	0	0	0	0
	1,586	2,390	2,773	3,086	3,463	2,369	3,030	3,244	3,516	4,180	4,224
Total assets	2,543	3,261	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911	4,922

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	81.7%	63.2%	64.4%	63.7%	64%	63.9%	64.5%	64.9%
EBITDA margin %	27.2%	26.6%	31.8%	32%	33.4%	29%	32.5%	35.9%
EBIT margin %	23.7%	21.8%	26.9%	27.6%	29%	26.1%	29.8%	33.6%
PAT margin %	20.6%	23.7%	22.2%	23.5%	25.7%	25.1%	33.7%	28.7%
Working capital
Receivable days	30	29	18	20	23	31	31	26
Inventory days	371	198	199	173	175	200	214	195
Payable days	—	—	130	102	91	77	68	89
NWC days	—	—	87	91	107	154	177	132
Leverage
Current ratio	3.05	3.49	2.46	2.77	3.79	5.01	6.17	6.06
Debt to EBITDA	0	0	0	0	0	0	0	0
Debt to equity	0	0	0	0	0	0	0	0
Interest coverage	512.6	60.2	45.3	74.7	60.1	48.9	101.3	109.1
Asset turnover	0.53	0.49	0.69	0.67	0.61	0.52	0.46	0.51
Return ratios
Return on assets %	10.9%	11.6%	15.2%	15.7%	15.6%	13%	15.6%	14.7%
Return on capital employed %	22.9%	19.9%	22.7%	28.3%	25.2%	21.5%	21.2%	24%
Return on equity %	14.2%	15%	20.8%	21.4%	19.5%	15.3%	18.2%	17.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%
	2.82%	3.03%	3.33%	3.22%	3.54%	2.75%	2.18%	2.39%	2.6%	2.71%	2.81%	1.65%
	15.01%	15.15%	15.33%	15.84%	16.03%	16.79%	17.1%	17.23%	17.1%	17.05%	16.89%	17.8%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	18.25%	17.9%	17.42%	17.02%	16.51%	16.54%	16.8%	16.46%	16.38%	16.32%	16.38%	16.63%
No. of shareholders	—	—	—	—	—	—	—	—	1,03,480	1,00,933	99,545	1,02,478

Promoter holding up 0 percentage points since Sep 2023.

3 deals · 24 Apr 2026 – 20 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
20 Aug 2026	QUANT MUTUAL FUND	Bulk	BSE	Buy	2,67,864	₹4,899.97	₹131.25 Cr
24 Apr 2026	GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO	Bulk	BSE	Sell	4,26,066	₹4,700.01	₹200.25 Cr
24 Apr 2026	PRUDENTIAL ICICI MUTUAL FUND A/C DISCOVERY FUND	Bulk	BSE	Buy	4,00,000	₹4,700.00	₹188.00 Cr

1–3 of 3

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Pradip Panalal ShahNon-Executive - Non Independent Director-Chairperson
Ms. Meena GaneshNon-Executive - Independent Director
Mr. Lakshmanan KrishnakumarNon-Executive - Independent Director
Ms. Sonia SinghNon-Executive - Independent Director
Ms. Meenakshi NevatiaExecutive Director-CEO-MD
Mr. Amit AgarwalExecutive Director
Mr. P RenganExecutive Director
Mr. Amit AgarwalExecutive Officer & Chief Financial Officer
Prajeet NairCompany Secretary and Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 11 fund houses

Held by these funds

7.26%

of the company's equity

All mutual funds

12.68%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

41 schemes · 11 fund houses

		Shares
SMALL CAP FUND	Nippon India Mutual Fund	12.06 L	564.99	0.68%	2.639%	-0
Small Cap FundNEW	ICICI Prudential Mutual Fund	3.57 L	167.22	1.7%	0.781%	—
Multi Cap FundNEW	Nippon India Mutual Fund	3.56 L	166.99	0.3%	0.78%	—
PHARMA FUND	Nippon India Mutual Fund	3.18 L	149.08	1.57%	0.696%	-0
Healthcare FundNEW	ICICI Prudential Mutual Fund	2.77 L	129.99	1.86%	0.607%	—
Healthcare Fund	DSP Mutual Fund	2.64 L	123.49	3.22%	0.577%	+57,949
Large & Mid Cap Fund	DSP Mutual Fund	1.78 L	83.43	0.45%	0.39%	-0
INDIA PHARMA & HEALTHCARE FUND	Tata Mutual Fund	97,680	45.76	2.92%	0.214%	-0

1–8 of 41

1 / 6

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

16 announcementsExport CSV

29 Sept 2026, 4:54 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	81.7%	63.2%	64.4%	63.7%	64%	63.9%	64.5%	64.9%
EBITDA margin %	27.2%	26.6%	31.8%	32%	33.4%	29%	32.5%	35.9%
EBIT margin %	23.7%	21.8%	26.9%	27.6%	29%	26.1%	29.8%	33.6%
PAT margin %	20.6%	23.7%	22.2%	23.5%	25.7%	25.1%	33.7%	28.7%
Working capital
Receivable days	30	29	18	20	23	31	31	26
Inventory days	371	198	199	173	175	200	214	195
Payable days	—	—	130	102	91	77	68	89
NWC days	—	—	87	91	107	154	177	132
Leverage
Current ratio	3.05	3.49	2.46	2.77	3.79	5.01	6.17	6.06
Debt to EBITDA	0	0	0	0	0	0	0	0
Debt to equity	0	0	0	0	0	0	0	0
Interest coverage	512.6	60.2	45.3	74.7	60.1	48.9	101.3	109.1
Asset turnover	0.53	0.49	0.69	0.67	0.61	0.52	0.46	0.51
Return ratios
Return on assets %	10.9%	11.6%	15.2%	15.7%	15.6%	13%	15.6%	14.7%
Return on capital employed %	22.9%	19.9%	22.7%	28.3%	25.2%	21.5%	21.2%	24%
Return on equity %	14.2%	15%	20.8%	21.4%	19.5%	15.3%	18.2%	17.2%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
29 Sept 2026, 4:54 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
29 Sept 2026, 1:19 pm	Company Update General	Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.	PDF
18 Sept 2026, 4:26 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management	PDF
7 Sept 2026, 11:24 am	Others Outcome without intimation	Board Meeting Outcome for Discontinuation Of Minipress XL.	PDF
29 Jul 2026, 7:20 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
28 Jul 2026, 7:03 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
28 Jul 2026, 1:52 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30, 2026.	PDF
27 Jul 2026, 4:32 pm	Company Update Change in Directorate	Announcement under Regulation 30 (LODR)-Change in Directorate	PDF

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	345	329	332	98	323	427	667	356	257	660	968
	-701	-250	-238	35	1,530	-469	-575	-36	54	-71	-562
	-62	-83	-110	-110	-164	-1,571	-181	-346	-235	-205	-798
Net cash flow	-417	-3	-17	23	1,690	-1,613	-88	-26	75	383	-392
Free cash flow	302	304	244	93	306	410	652	291	238	632	942
CFO / Operating profit %	80.2%	98.8%	66.3%	17.3%	56.4%	60%	79.8%	44%	40.4%	89.1%	107%

Pfizer Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Announcements

Not in the F&O segment

Announcements

Annual reports

27

1

Compounded sales growth

Compounded profit growth

Return on equity

Pfizer Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Announcements

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

Announcements

Annual reports

Dividends27

Board meetings1

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

27

1